Despite this encouraging profile as a direct-acting antiviral candidate agent for HIV infection, it was not further developed as an HIV clinical candidate following its acquisition by Allergan, but investigated instead for potential therapy of NASH with liver fibrosis, due to the pharmacologies associates with CCR2 and CCR5 in this disease [27,28]. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.